What top creators are saying about Novartis AG(NVS)

Part of the European large-caps considered unattractive compared to U.S. growth assets.

Took a seat on the Anthropic Board to influence the direction of AI in the pharmaceutical industry.

Aggressively using M&A to mitigate patent cliffs and protect market dominance in the allergy sector.

Acquired Accelergy for $2 billion to bolster its immunology pipeline and replace revenue from drugs with expiring patents.

The CEO presents a strong case that the company's focused strategy, strong competitive moat in areas like Radioligand Therapy, and deep integration of AI have created a more agile, innovative, and valuable business with clear growth drivers.

Listed on the watchlist of AI-focused pharmaceutical companies expected to 'outperform' for the rest of the year due to AI-driven efficiencies in drug development.

Benefits from a highly favorable regulatory environment where the FDA is reducing barriers and accelerating approvals for cell and gene therapies, including CAR-T.

Cited as an example of an incumbent that struggles with internal innovation but can succeed by 'renting' innovation from startups through partnerships, licensing, and acquisitions.

Has a historical connection to the origins of psychedelic research (LSD) through its acquisition of Sandoz. While not currently a 'psychedelic stock,' this history is noted as relevant to the entire sector's regulatory landscape.

Access to Isomorphic Labs' AI drug discovery engine provides a major potential competitive advantage and could accelerate R&D. Positive news from preclinical trials in 2025 could be a significant stock driver.

Is set to acquire Tourmaline Bio, participating in a broader surge in M&A activity which can be a sign of economic confidence.

Using Palantir's AIP to accelerate drug discovery. Success in this area is described as potentially 'revolutionary for the pharmaceutical industry,' indicating significant upside potential.

Included on a global watchlist of large-cap pharma companies to track the sector, with no specific buy or sell thesis mentioned.

Mentioned only as a potential acquirer of Abivax for approximately $15 billion.

A more conservative way to invest in the AI drug discovery theme by leveraging partnerships with specialized firms like BenevolentAI.

Mentioned for comparison, as its drug Picray is considered less effective than Cel-Sci's Jedatolisib. No direct investment thesis was provided for Novartis itself.